Kite Pharma - A Gilead Company
In The NEWS
Gilead Sciences' (GILD) firm Kite Pharma, announced that the European Commission (EC) has approved its CAR T-cell therapy Yescarta® (axicabtagene ciloleucel) for adult patients with relapsed or refractory follicular lymphoma (FL) after three or more lines of systemic therapy.
Yescarta maintained its orphan medicinal product designation in this indication.
From . . .